Silexion Induces Warrant Exercise at $0.26, Raising $0.84M and Issuing 6.4M New Warrants
SLXN sits 35% above its 52-week low of $0.236 on elevated volume (24× avg).
Summary
Silexion is inducing early exercise of 3.2M Series E warrants at $0.2603 to raise ~$0.84M, while issuing 6.4M new warrants at the same price — a highly dilutive structure for a company with a ~$3.5M market cap.
Key Events · Financing and Capital Events · SLXN
-
Warrant Inducement Exercise
Holders of 3,216,928 Series E warrants agreed to exercise for cash at a reduced price of $0.2603 per share, generating approximately $0.84 million in gross proceeds.
-
New Warrants Double Dilution
In exchange, the company will issue 6,433,856 new warrants (3,216,928 Series F and 3,216,928 Series G) at an exercise price of $0.2603 per share — 200% of the exercised amount.
-
Series E Exercise Price Cut
The exercise price for all outstanding Series E warrants (3,846,161 shares) is being reduced to $0.2603 per share, increasing potential dilution across the entire warrant class.
-
Shareholder Approval Required
New warrants are exercisable only after shareholders approve an increase in authorized shares — a proposal they rejected on September 25, 2026, just four days before this agreement.
Analysis · SLXN · Life Sciences
Silexion is inducing holders of 3.2 million Series E warrants to exercise early at a reduced price of $0.2603 per share, generating roughly $0.84 million in gross proceeds. In exchange, the company is issuing 6.4 million new warrants — double the exercised amount — at the same $0.2603 strike. This is a deeply dilutive structure for a company with a market cap of only about $3.5 million and a stock trading at $0.3186. The new warrants cannot be exercised until shareholders approve an increase in authorized shares, which they rejected just four days ago on September 25. The company is also cutting the exercise price on all outstanding Series E warrants to $0.2603, further increasing potential dilution. Against a backdrop of going-concern doubts, Nasdaq delisting notices, and a failed reverse split vote, this financing is a survival move that comes at a steep cost to existing holders.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.6% of the 972 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.24 to $42.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.